Yan Ji
Impact in
- Oncology top 5%
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
- Cancer Research top 5%
Papers in
-
- Genomics, phytochemicals, and oxidative stress 7
- Oncology 35
- HER2/EGFR in Cancer Research 8
- Cancer-related Molecular Pathways 8
- Cancer Treatment and Pharmacology 8
- Drug Transport and Resistance Mechanisms 5
- Co-authors
- Marilyn E. Morris (6 shared papers)George P. Studzinski (4 shared papers)Nanjoo Suh (7 shared papers)Hong Jin Lee (6 shared papers)Wei Yan (3 shared papers)Handong Wang (3 shared papers)Gang Chen (2 shared papers)Yuhsin Kuo (1 shared paper)
- Journals
- Cancer Research (8 papers)Arteriosclerosis Thrombosis and Vascular Biology (4 papers)Annals of Oncology (4 papers)The Journal of Clinical Pharmacology (3 papers)Biochemical Pharmacology (3 papers)
- Partner nations
- United StatesChinaSwitzerland
In The Last Decade
Yan Ji
111 papers receiving 3.0k citations
Yan Ji's Hit Papers
Peers
Comparison fields: 5 of 126
- Oncology 611
- Cancer Research 319
- Geriatrics and Gerontology 72
- Molecular Biology 1.3k
- Immunology 354
Countries citing papers authored by Yan Ji
This map shows the geographic impact of Yan Ji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Ji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Ji more than expected).
Fields of papers citing papers by Yan Ji
This network shows the impact of papers produced by Yan Ji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Ji. The network helps show where Yan Ji may publish in the future.
Co-authors
The 25 scholars most cited alongside Yan Ji, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 116 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival Hit paper breakdown → | 2021 | 174 |
| 2 | 2008 | 152 | |
| 3 | 2009 | 143 | |
| 4 | 2021 | 119 | |
| 5 | 2015 | 114 | |
| 6 | 2005 | 90 | |
| 7 | 2008 | 89 | |
| 8 | 2015 | 87 | |
| 9 | 2004 | 85 | |
| 10 | 2003 | 83 | |
| 11 | 2019 | 78 | |
| 12 | 2006 | 74 | |
| 13 | 2019 | 73 | |
| 14 | 2020 | 71 | |
| 15 | 2006 | 58 | |
| 16 | 2015 | 55 | |
| 17 | 2012 | 53 | |
| 18 | 2018 | 49 | |
| 19 | 2020 | 49 | |
| 20 | 2005 | 49 |
About Yan Ji
Yan Ji is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Genetics, having authored 116 papers that have together received 3.1k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (22 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (8 papers), Cancer-related Molecular Pathways (8 papers), Cancer Treatment and Pharmacology (8 papers), Genomics, phytochemicals, and oxidative stress (7 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Drug Transport and Resistance Mechanisms (5 papers). The work is most often cited by research in Oncology (611 citations), Cancer Research (319 citations), Geriatrics and Gerontology (72 citations), Molecular Biology (1.3k citations) and Immunology (354 citations). Yan Ji has collaborated with scholars based in United States, China and Switzerland. Frequent co-authors include Marilyn E. Morris, George P. Studzinski, Nanjoo Suh, Hong Jin Lee, Wei Yan, Handong Wang, Gang Chen, Yuhsin Kuo, Shiby Paul and Bandaru S. Reddy. Their work appears in journals such as Cancer Research, Arteriosclerosis Thrombosis and Vascular Biology, Annals of Oncology, The Journal of Clinical Pharmacology and Biochemical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.